《Nature,11月21日,The association between body mass index class and coronavirus disease 2019 outcomes》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-12-22
  • The association between body mass index class and coronavirus disease 2019 outcomes
    Abdallah Al-Salameh, Jean-Philippe Lanoix, Youssef Bennis, Claire Andrejak, Etienne Brochot, Guillaume Deschasse, Hervé Dupont, Vincent Goeb, Maité Jaureguy, Sylvie Lion, Julien Maizel, Julien Moyet, Benoit Vaysse, Rachel Desailloud, Olivier Ganry, Jean-Luc Schmit & Jean-Daniel Lalau
    International Journal of Obesity (2020)

    Abstract
    Background/Objectives
    A growing body of data suggests that obesity influences coronavirus disease 2019 (COVID-19). Our study’s primary objective was to assess the association between body mass index (BMI) categories and critical forms of COVID-19.

    Subjects/Methods
    Data on consecutive adult patients hospitalized with laboratory-confirmed COVID-19 at Amiens University Hospital (Amiens, France) were extracted retrospectively. The association between BMI categories and the composite primary endpoint (admission to the intensive care unit or death) was probed in a logistic regression analysis.

    Results
    In total, 433 patients were included, and BMI data were available for 329: 20 were underweight (6.1%), 95 have a normal weight (28.9%), 90 were overweight (27.4%), and 124 were obese (37.7%). The BMI category was associated with the primary endpoint in the fully adjusted model; the odds ratio (OR) [95% confidence interval (CI)] for overweight and obesity were respectively 1.58 [0.77–3.24] and 2.58 [1.28–5.31]. The ORs [95% CI] for ICU admission were similar for overweight (3.16 [1.29–8.06]) and obesity (3.05 [1.25–7.82]) in the fully adjusted model. The unadjusted ORs for death were similar in all BMI categories while obesity only was associated with higher risk after adjustment.

    Conclusions
    Our results suggest that overweight (and not only obesity) is associated with ICU admission, but overweight is not associated with death.

  • 原文来源:https://www.nature.com/articles/s41366-020-00721-1
相关报告
  • 《JAMA,6月26日,Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-28
    • Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis Céline Louapre, MD1; Nicolas Collongues, MD2; Bruno Stankoff, MD1,3; et al Claire Giannesini, MD3; Caroline Papeix, MD1; Caroline Bensa, MD4; Romain Deschamps, MD4; Alain Créange, MD5; Abir Wahab, MD5; Jean Pelletier, MD6; Olivier Heinzlef, MD7; Pierre Labauge, MD8; Laurent Guilloton, MD9; Guido Ahle, MD10; Mathilde Goudot, MD11; Kevin Bigaut, MD2; David-Axel Laplaud, MD12; Sandra Vukusic, MD13; Catherine Lubetzki, MD1; Jérôme De Sèze, MD2; for the Covisep investigators Author Affiliations Article Information JAMA Neurol. Published online June 26, 2020. doi:10.1001/jamaneurol.2020.2581 Abstract Importance  Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. Objective  To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. Design, Setting, and Participants  The Covisep registry is a multicenter, retrospective, observational cohort study conducted in MS expert centers and general hospitals and with neurologists collaborating with MS expert centers and members of the Société Francophone de la Sclérose en Plaques. The study included patients with MS presenting with a confirmed or highly suspected diagnosis of COVID-19 between March 1, 2020, and May 21, 2020.
  • 《TMID,1月30日,The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-03
    • The atypical pneumonia case, caused by a novel coronavirus (2019-nCoV), was first identified and reported in Wuhan, China in December, 2019 [1]. As of January 21, 2020 (11:59 a.m., GMT+8), there have been 215 cases of 2019-nCoV infections confirmed in mainland China. There were 198 domestic cases in Wuhan including 4 deaths, and 17 cases identified outside Wuhan including 8 in Shenzhen, 5 in Beijing, 2 in Shanghai and 2 in other places. The 2019-nCoV cases were also reported in Thailand, Japan and Republic of Korea, and all these cases were exported from Wuhan China, see WHO news release https://www.who.int/csr/don/en/from January 14–20, 2020. The first case outside Wuhan was confirmed in Shenzhen on January 3, 2020. Then, many major Chinese cities reported events of ‘imported 2019-nCoV cases’, thereafter, including Beijing and Shanghai. The outbreak is still on-going. And a recently published preprint by Imai et al. estimated that a total of 1723 (95%CI: 427–4471) cases of 2019-nCoV infections in Wuhan had onset of symptoms by January 12, 2020 [2].